[Federal Register Volume 86, Number 145 (Monday, August 2, 2021)]
[Notices]
[Pages 41488-41490]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-16384]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2002-N-0314]


Agency Information Collection Activities; Submission for Office 
of Management and Budget Review; Comment Request; Request for Samples 
and Protocols

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or we) is announcing 
that a proposed collection of information has been submitted to the 
Office of Management and Budget (OMB) for review and clearance under 
the Paperwork Reduction Act of 1995.

DATES: Submit written comments (including recommendations) on the 
collection of information by September 1, 2021.

ADDRESSES: To ensure that comments on the information collection are 
received, OMB recommends that written comments be submitted to https://www.reginfo.gov/public/do/PRAMain.

[[Page 41489]]

Find this particular information collection by selecting ``Currently 
under Review--Open for Public Comments'' or by using the search 
function. The OMB control number for this information collection is 
0910-0206. Also include the FDA docket number found in brackets in the 
heading of this document.

FOR FURTHER INFORMATION CONTACT: Domini Bean, Office of Operations, 
Food and Drug Administration, Three White Flint North, 10A-12M, 11601 
Landsdown St., North Bethesda, MD 20852, 301-796-5733, 
PRAStaff@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has 
submitted the following proposed collection of information to OMB for 
review and clearance.

Request for Samples and Protocols

OMB Control Number 0910-0206--Extension

    This information collection supports Agency regulations. Under 
section 351 of the Public Health Service Act (42 U.S.C. 262), FDA has 
the responsibility to issue regulations that prescribe standards 
designed to ensure the safety, purity, and potency of biological 
products and to ensure that the biologics licenses for such products 
are only issued when a product meets the prescribed standards. Under 
Sec.  610.2 (21 CFR 610.2), the Center for Biologics Evaluation and 
Research (CBER) or the Center for Drug Evaluation and Research may at 
any time require manufacturers of licensed biological products to 
submit to FDA samples of any lot, along with the protocols showing the 
results of applicable tests, prior to distributing the lot of the 
product. In addition to Sec.  610.2, there are other regulations that 
require the submission of samples and protocols for specific licensed 
biological products: Sec. Sec.  660.6, 660.36, and 660.46 (21 CFR 
660.6, 660.36, and 660.46).
    Section 660.6(a) provides requirements for the frequency of 
submission of samples from each lot of Antibody to Hepatitis B Surface 
Antigen product, and Sec.  660.6(b) provides the requirements for the 
submission of a protocol containing specific information along with 
each required sample. For Sec.  660.6 products subject to official 
release by CBER, one sample from each filling of each lot is required 
to be submitted along with a protocol consisting of a summary of the 
history of manufacture of the product, including all results of each 
test for which test results are requested by CBER. After official 
release is no longer required, one sample along with a protocol is 
required to be submitted at 90-day intervals. In addition, samples, 
which must be accompanied by a protocol, may at any time be required to 
be submitted to CBER if continued evaluation is deemed necessary.
    Section 660.36(a) requires, after each routine establishment 
inspection by FDA, the submission of samples from a lot of final 
Reagent Red Blood Cell product along with a protocol containing 
specific information. Section 660.36(a)(2) requires that a protocol 
contain information, including, but not limited to, manufacturing 
records, certain test records, and identity test results. Section 
660.36(b) requires a copy of the antigenic constitution matrix 
specifying the antigens present or absent to be submitted to the CBER 
Director at the time of initial distribution of each lot.
    Section 660.46(a) contains requirements as to the frequency of 
submission of samples from each lot of Hepatitis B Surface Antigen 
product, and Sec.  660.46(b) contains the requirements as to the 
submission of a protocol containing specific information along with 
each required sample. For Sec.  660.46 products subject to official 
release by CBER, one sample from each filling of each lot is required 
to be submitted along with a protocol consisting of a summary of the 
history or manufacture of the product, including all results of each 
test for which test results are requested by CBER. After notification 
of official release is received, one sample along with a protocol is 
required to be submitted at 90-day intervals. In addition, samples, 
which must be accompanied by a protocol, may at any time be required to 
be submitted to CBER if continued evaluation is deemed necessary.
    Samples and protocols are required by FDA to help ensure the 
safety, purity, or potency of the product because of the potential lot-
to-lot variability of a product produced from living organisms. In 
cases of certain biological products (e.g., Albumin, Plasma Protein 
Fraction, and therapeutic biological products) that are known to have 
lot-to-lot consistency, official lot release is not normally required. 
However, submissions of samples and protocols of these products may 
still be required for surveillance, licensing, and export purposes, or 
in the event that FDA obtains information that the manufacturing 
process may not result in consistent quality of the product.
    The following burden estimate is for the protocols required to be 
submitted with each sample. The collection of samples is not a 
collection of information under 5 CFR 1320.3(h)(2). Respondents to the 
collection of information under Sec.  610.2 are manufacturers of 
licensed biological products. Respondents to the collection of 
information under Sec. Sec.  660.6(b), 660.36(a)(2) and (b), and 
660.46(b) are manufacturers of the specific products referenced 
previously in this document. The estimated number of respondents for 
each regulation is based on the annual number of manufacturers that 
submitted samples and protocols for biological products, including 
submissions for lot release, surveillance, licensing, or export. Based 
on information obtained from FDA's database system, approximately 75 
manufacturers submitted samples and protocols in fiscal year (FY) 2020 
under the regulations cited previously in this document. FDA estimates 
that approximately 72 manufacturers submitted protocols under Sec.  
610.2, and 3 manufacturers submitted protocols under the regulation 
(Sec.  660.6) for the other specific product. FDA received no 
submissions under Sec. Sec.  660.36 or 660.46; however, FDA is using 
the estimate of one protocol submission under each regulation in the 
event that protocols are submitted in the future.
    The estimated total annual responses are based on FDA's final 
actions completed in FY 2020 for the various submission requirements of 
samples and protocols for the licensed biological products. The average 
burden per response is based on information provided by industry. The 
burden estimates provided by industry ranged from 1 hour to 5.5 hours. 
Under Sec.  610.2, the hours per response are based on the average of 
these estimates and rounded to 3 hours. Under the remaining 
regulations, the average burden per response is based on the higher end 
of the estimate (rounded to 5 or 6 hours) because more information is 
generally required to be submitted in the other protocols than under 
Sec.  610.2.
    In the Federal Register of March 16, 2021 (86 FR 14448), we 
published a 60-day notice requesting public comment on the proposed 
collection of information. No comments were received.
    We estimate the burden of this collection of information as 
follows:

[[Page 41490]]



                                 Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
                                                     Number of
     21 CFR section/activity         Number of     responses per   Total annual   Average burden    Total hours
                                    respondents     respondent       responses     per response
----------------------------------------------------------------------------------------------------------------
610.2, Requests for Samples and               72          82.972           5,974               3          17,922
 Protocols; Official Release....
660.6(b), Protocols.............               3               4              12               5              60
660.36(a)(2) and (b), Samples                  1               1               1               6               6
 and Protocols..................
660.46(b), Protocols............               1               1               1               5               5
                                 -------------------------------------------------------------------------------
    Total.......................              77  ..............           5,988  ..............          17,993
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
  information.

    Our estimated burden for the information collection reflects an 
overall decrease of 1,463 hours and a corresponding decrease of 491 
responses. We attribute this adjustment to a decrease in the number of 
submissions we received over the last few years.

    Dated: July 27, 2021.
Lauren K. Roth,
Acting Principal Associate Commissioner for Policy.
[FR Doc. 2021-16384 Filed 7-30-21; 8:45 am]
BILLING CODE 4164-01-P


